Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from Chardan Capital

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by Chardan Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $35.00 target price on the stock. Chardan Capital’s price objective would suggest a potential upside of 6.48% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Needham & Company LLC lifted their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, January 5th. UBS Group set a $50.00 target price on Stoke Therapeutics in a research report on Monday, December 15th. HC Wainwright lifted their price target on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Wedbush boosted their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.83.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $32.87 on Wednesday. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $40.22. The firm’s 50-day moving average is $32.69 and its two-hundred day moving average is $29.89. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 49.06 and a beta of 1.07.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.22). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $1.40 million during the quarter, compared to the consensus estimate of $5.32 million. On average, equities analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 33,243 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the sale, the director directly owned 283,302 shares in the company, valued at $11,258,421.48. This trade represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Arthur Tzianabos sold 4,355 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the completion of the transaction, the insider directly owned 31,339 shares in the company, valued at $1,253,560. This represents a 12.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 38,203 shares of company stock valued at $1,517,541 in the last three months. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics during the 4th quarter valued at about $26,000. Harbour Investments Inc. boosted its holdings in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares in the last quarter. Generali Investments Management Co LLC acquired a new stake in Stoke Therapeutics in the third quarter worth about $41,000. BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.